Ophthalmology is a specialized field of medicine that focuses on the health of the eye. It includes the anatomy, physiology, and diseases that may affect the eye. Whereas, ophthalmic drugs are used to treat various disorders associated with the eyes, such as cataracts, glaucoma, infection, allergy, and inflammation, retinal disorders (such as wet age-related macular degeneration, dry age-related macular degeneration, diabetic retinopathy, and others), and other ophthalmic disorders.
Rise in prevalence of ophthalmic disorders, growing geriatric population, rise in demand for safe and effective ophthalmic drugs, rise in focus on the development of ophthalmic drugs, and increase in research and development are major factors expected to propel growth of the global ophthalmic drugsmarket during the forecast period.
For instance, in April 2022, Sandoz announced the US launch of its generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%, AB-rated generic equivalent to AbbVie’s COMBIGAN, to lower eye pressure in patients with ocular hypertension. Moreover, in March 2022, Théa Pharma acquired seven branded ophthalmic products from Akorn Operating Company LLC to strengthen its position as a significant provider of products developed to satisfy the demands of eye care specialists across the United States.
- This report provides in-depth analysis of the global ophthalmic drugsmarket, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global ophthalmic drugsmarket based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Abbvie Inc. (Allergan Plc), Alcon, Inc., Novartis AG, Pfizer Inc., Bausch & Lomb Incorporated, F. Hoffmann-LA Roche Ltd. (Genentech, Inc.), among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global ophthalmic drugsmarket report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ophthalmic drugsmarket.
-
- Dry Eye
- Glaucoma
- Infection/Inflammation/Allergy
- Retinal Disorder
- Wet Age-related Macular Degeneration
- Dry Age-related Macular Degeneration
- Diabetic Retinopathy
- Others
- Others
-
- Prescription Drugs
- Over-the-counter Drugs
-
- Liquid Ophthalmic Drug Forms
- Solid Ophthalmic Drug Forms
- Semisolid Ophthalmic Drug Forms
- Multicompartment Drug Delivery Systems
- Other Ophthalmic Drug Forms
-
- Hospital Pharmacies
- Drug Stores
- Online Pharmacies
- Others
-
- Anti-glaucoma
- Anti-infection
- Anti-inflammation
- Anti-allergy
- Others
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
-
- Abbvie Inc. (Allergan Plc)
- Alcon, Inc.
- Novartis AG
- Pfizer Inc.
- Bausch & Lomb Incorporated
- Hoffmann-LA Roche Ltd. (Genentech, Inc.)
